Evaluation of the clinical relevance of the anionic glutathione-s-transferase (GSTπ and multidrug resistance (mdr-1) gene coexpression in leukemias and lymphomas

D. Russo, J. P. Marie, D. C. Zhou, A. M. Faussat, C. Melli, D. Damiani, A. Michelutti, M. Michieli, R. Fanin, M. Baccarani, R. Zittoun

Research output: Contribution to journalArticlepeer-review

Abstract

By using RNA slot-blot technique, the frequency and the degree of GSTπ and mdr-1 gene coexpression were investigated in 23 AML patients, 9 ALL, 9 CLL and 11 cases of NHL in an attempt to study their clinical and prognostic relevance. GSTπ and mdr-1 levels were expressed as arbitrary units (U) with respect to the negative controls (U = 0), MCF7 and HL60 sensitive cell lines, and the positive controls (U = 10), MCF7/DOXO and HL60/DNR resistant cell lines. The concomitant GSTπmdr1 gene overexpression showed a negative prognostic value in the set of newly diagnosed AML pts (10 cases), furthermore higher GSTπ and mdrl mRNA levels were averagely detected in the relapsed/resistant ALL pts (4 cases), and in CLL (7 cases) and NHL (8 cases) heavily pretreated patients who were unresponsive to chemotherapy and with a disease progression. These preliminary data show that two different mechanisms of drug resistance can be coexpressed at the same time in those leukemias and lymphomas with a clinically unfavourable course.

Original languageEnglish
Pages (from-to)453-468
Number of pages16
JournalLeukemia and Lymphoma
Volume15
Issue number5-6
DOIs
Publication statusPublished - 1994

Keywords

  • GSTπ
  • Leukemia
  • Lymphoma
  • Mdr-1

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Evaluation of the clinical relevance of the anionic glutathione-s-transferase (GSTπ and multidrug resistance (mdr-1) gene coexpression in leukemias and lymphomas'. Together they form a unique fingerprint.

Cite this